Catamaran Bio

Catamaran Bio is a biotechnology company based in Boston, founded in 2020.

The company specializes in engineering allogeneic, off-the-shelf CAR-NK cell therapies aimed at treating solid tumors and other cancers. By leveraging the natural cancer-fighting abilities of natural killer (NK) cells, along with synthetic biology and non-viral cell engineering, Catamaran Bio develops innovative treatments for patients with significant unmet medical needs. The company's mission is to create safe and effective immune cell therapies for cancer and immune disorders using its proprietary TAILWINDTM Platform. Catamaran Bio is focused on drug discovery and development, with its therapeutic candidates currently in the preclinical stage. The company aims to make cell therapies more accessible and effective, targeting patients with solid tumors and immune disorders. With a dedicated team of approximately 41 employees, Catamaran Bio is committed to advancing healthcare solutions in the oncology and immune disorder sectors.